Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group has sued the U.

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its official shortage list arbitrarily and without warning.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. | Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight.

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another lawsuit against the U.S. Food and Drug Administration (FDA). This time, it’s over the health regulator’s decision to remove semaglutide — the active ingredient in Novo Nordisk’s (NVO) popular Ozempic and Wegovy treatments — from its drug shortage list.